Novel molecular aspects of pituitary adenomas

Area of Science:

• Endocrinology
• Cell Biology
• Molecular Biology

Background:

• Ghrelin and somatostatin are functional antagonists in regulating growth hormone (GH) release.
• Their opposing roles extend to cellular proliferation in various tissues.
• Pituitary adenomas are associated with altered p27 peptide content, a cell cycle inhibitor.

Purpose of the Study:

• To investigate the differential effects of ghrelin and somatostatin on pituitary cell proliferation.
• To elucidate the molecular mechanisms underlying these effects, particularly involving the MAPK pathway and p27.
• To assess the potential role of ghrelin in pituitary tumorigenesis and the antiproliferative action of somatostatin analogs.

Main Methods:

• Utilized rat pituitary cell line (GH3) and human somatotrophinoma cells.
• Administered ghrelin, desoctanoyl ghrelin, octreotide, and SOM230.
• Assessed cell proliferation and activation of mitogen-activated protein kinase (MAPK), tyrosine kinase, and protein kinase C.
• Measured p27 protein levels via Western blotting or similar techniques.

Main Results:

• Ghrelin and desoctanoyl ghrelin stimulated proliferation in GH3 cells, inhibited by MAPK, tyrosine kinase, and protein kinase C inhibitors.
• Somatostatin and its analogs inhibited MAPK activation in pituitary cells.
• Octreotide and SOM230 upregulated p27 protein levels in human somatotrophinoma cells.

Conclusions:

• Ghrelin and somatostatin exhibit opposing effects on somatotroph cell proliferation, mirroring their roles in GH release.
• Ghrelin may contribute to pituitary tumorigenesis through autocrine/paracrine signaling.
• The antiproliferative effects of somatostatin analogs involve p27 upregulation and MAPK pathway downregulation in human somatotrophinomas.